Programme

This is a Provisional Conference Programme.

For further information on this event please contact us.

Welcome & Opening Remarks

SESSION 1:
OPENING PLENARY SESSION

Moderator: Mark R. Prausnitz
(Georgia Institute of Technology, Atlanta, Georgia, USA)

Opening Keynote:
‘Skin delivery: Lotions, potions and more radical notions’

James Birchall
(Cardiff University, Cardiff, Wales, UK)

‘Immunological niche in skin to exploit for vaccination’Shreemanta K. Parida
(Karolinska Institute, Stockholm, Sweden)

‘Targeting Skin Dendritic cells’
Esther C. de Jong
(Dept. Experimental Immunology, Amsterdam UMC, Amsterdam, The Netherlands)

Coffee Break

SESSION 2:
GLOBAL

Moderator: Shreemanta K. Parida
(Karolinska Institute, Stockholm, Sweden)

‘Understanding program needs and suitability of microarray patch technology for global health’
Jennifer Foster, Annie Rein-Weston, Collrane Frivold, Priyanka Bajaj, Shubham Kesharwani, Darin Zehrung and Courtney Jarrahian 
(PATH, Seattle, Washington, USA)

‘The experience of intradermal administration of fractional dose inactivated poliovirus by the Global Polio Eradication Initiative (GPEI)’
Grace Macklin
(World Health Organization, Geneva, Switzerland)

‘Quantitative and qualitative assessment of different techniques of intradermal administration of fractional dose IPV in campaign setting in the Gambia’
Vishali Jeyaseelan
(World Health Organization, Geneva, Switzerland)

Lunch Break & Posters Set-Up

SESSION 3:
MICROARRAY TECHNOLOGY & RESPONSES

Moderator: Anne Moore
(University College Cork, Cork, Ireland)

‘Innate local response and tissue recovery following application of high-density microarray patches to human skin’
David A. Muller1, Joakim Henricson2,3, S. Ben Baker4, Totte Togö5, Cesar M. Jayashi4, Pierre A. Lemaire4, Angus Forster4, Paul R. Young1 and Christopher D. Anderson6,7
(1 School of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australia; 2 Department of Medical and Health Sciences, Faculty of Health Sciences, Linköping University, Linköping, Sweden; 3 Department of Emergency Medicine, Local Health Care Services in Central Östergötland, Sweden; 4 Vaxxas Pty Ltd, Translational Research Institute, Woolloongabba, Queensland, Australia; 5 Allergy Center Linköping, Region Östergötland, Sweden; 6 Division of Cell Biology, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Sweden; 7 Department of Clinical and Experimental Medicine, Linköping University, Region Östergötland, Sweden)

Staphylococcus aureus affects skin inflammation through specific molecular interactions with Langerhans cells’
N. van Sorge
(UMC Utrecht, Medical Microbiology, Utrecht, The Netherlands)

‘NanoVAX®, a mucosal adjuvant enhances uptake and adjuvants epicutaneously delivered vaccines and Shifting the  immune response from Th2 to Th1 and mucosal immunity, Th17’Ali I. Fattom
(Bluewillow Biologics, Ann Arbor, Michigan, USA)

‘Cellular responses at the site of microarray patch influenza vaccine delivery in a randomized, controlled phase I clinical trial’
Alexandra C.I. Depelsenaire1*, Katey Witham1*, Margaret Veitch2, James W. Wells2, Christopher D. Anderson3, Jason D. Lickliter4, Steve Rockman5,6, Jesse Bodle5, Julian Hickling7, Germain J.P. Fernando1,8, Angus H. Forster1
(1 Vaxxas Pty Ltd, Brisbane, Queensland, Australia; 2 The University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia; 3 Department of Clinical and Experimental Medicine, Linkoping University, Sweden; 4 Nucleus Network Pty Ltd, Melbourne, Victoria, Australia; 5Seqirus Pty Ltd, Parkville, Victoria, Australia; 6 Department of Microbiology and Immunology, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia; 7 Working in Tandem Ltd, Cambridge, UK; 8 The University of Queensland, School of Chemistry & Molecular Biosciences, Faculty of Science, Brisbane, Queensland, Australia)

SESSION 4:
MICRONEEDLE PATCHES

Moderator: Darin Zehrung
(PATH, Seattle, Washington, USA)

‘Measles and rubella vaccination by microneedle patch’
Mark R. Prausnitz, Jeong Woo Lee and Yasmione Gomaa
(Georgia Institute of Technology, Atlanta, Georgia, USA)

‘Defining the range of adjuvants suitable for use with dissolvable microneedle patches’
Anne Moore
(University College Cork, Cork, Ireland)

‘Inactivated rotavirus vaccine for skin vaccination using a microneedle patch: An update’
Baoming Jiang
(Centers for Disease Control and Prevention Atlanta, Georgia, USA)

‘Immunologic mechanisms of seasonal influenza vaccines delivered by microneedle patches’Nadine Rouphael
(Emory University, Atlanta, Georgia, USA)

Coffee Break & Posters

SESSION 5:
MICROARRAY PATCHES

Moderator: Baoming Jiang
(CDC, Atlanta, Georgia, USA)

‘The public health value of a microarray patch for delivery of inactivated poliovirus vaccine’
Collrane Frivold, Jennifer Foster, Mercy Mvundura, Shan Hsu, Manjari Quintanar-Solares and Courtney Jarrahian
(PATH, Seattle, Washington, SA)

‘Micro array patch technology an innovative approach for intradermal vaccine delivery’Stefan Henke
(LTS Lohmann Therapie-Systeme AG, Andernach, Germany)

‘Prioritization of microarray patch applications of global public health importance’ 
Courtney Jarrahian, Collrane Frivold, Jennifer Foster and Darin Zehrung
(PATH, Seattle, Washington, USA)

‘Evalutation of a novel insect-specific flavivirus chimera vaccine candidate delivered to the skin by high-density microarray patches in a dengue challenge mouse model’
Jovin J.Y. Choo, Laura Vet, J Hobson-Peters, Germain J.P. Fernando, R.A. Hall, P.R. Young and D.A. Muller
(Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Queensland, Australia)

Lunch Break & Posters

SESSION 6:
DELIVERY

Moderator: Markus Clemenz
(Verapido Medical GmbH, Villingen-Schwenningen, Germany)

‘Getting vaccine across the skin barrier: What can nanocarriers contribute?’
Annika Vogt
(Charité – Universitätsmedizin Berlin, Berlin, Germany)

‘Tight junction disrupting peptide enhances cutaneous vaccination’
Matthew G. Brewer1, Elizabeth A. Anderson1, Radha P. Pandya1, Anna DeBenedetto1, Takeshi Yoshida1, Thomas A. Hilimire2, Luis Martinez-Sobrido2, Lisa A. Beck1 and Benjamin L. Miller1
(Department of Dermatology1 and Microbiology and Immunology2, University of Rochester, Rochester, New York, USA)

‘Novel intradermal DNA-enhancing delivery mechanisms’
Kate E. Broderick
(Inovio Pharmaceuticals, San Diego, California, USA)

Tea Break & Posters

SESSION 7:
VACCINES & VACCINATION

Moderator: Esther de Jong
(University of Amsterdam, Amsterdam, The Netherlands)

‘ZIKA skin vaccination’
Jacob Beaver and Ioanna Skountzou
(Emory University, Atlanta, Georgia, USA)

‘Targeting citrullinated vimentin and enolase with cytotoxic CD4 T cells, relies upon MHC-II expression by tumors, reduces myeloid suppressor cells and directly kills tumor cells’
Victoria A. Brentville1, Rachael L. Metheringham1, Ian Daniels1, Suha Atabani2, Peter Symonds1, Katherine W. Cook1, Ruhul Choudhury1, Poonam Vaghela1, Mohamed Gijon1, Ghislaine Meiners3, Willem-Jan Krebber3, Cornelis J. Melief3,4 and Lindy G. Durrant1,2
(1 Scancell Limited Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK; 2 Academic Department of Clinical Oncology, University of Nottingham, City Hospital, Nottingham, UK)

‘A thermostable microneedle patch for tetanus toxoid vaccination’
Andrey V. Romanyuk1, Ioanna Skountzou2 and Mark R. Prausnitz1
(1 School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA; 2 Department of Microbiology & Immunology, Emory University, Atlanta, Georgia, USA)

‘Patchless administration of canine influenza vaccine on dog’s ear without hair removal using insertion-responsive microneedles (IRMNs)’
In-Jeong Choi, Woonsung Na, Myun-Hwan Ahn1, Aram Kang3, Seong-O Choi1, Seung-Ki Baek1, Daesub Song3* and Jung-Hwan Park4*
(1 QuadMedicine R&D Centre, QuadMedicine, Inc., Seongnam, Republic of Korea; 2 Department of Veterinary Virology, College of Veterinary Medicine, Chonnam National University, Gwangju, Republic of Korea; 3 College of Pharmacy, Korea University, Sejong, Republic of Korea; 4Department of BioNano Technology, Gachon University, Seongnam, Republic of Korea)

SESSION 8:
DEVICES

Moderator: To be confirmed

‘Commercial intradermal needle-free injection system: Advancing current and future injectables’
Chris Cappello
(Pharmajet Inc., Golden, Colorado, USA)

‘Dermaject, a novel device for accurate, safe and reproducible intradermal application’
Markus Clemenz
(Hahn-Schickard-Gesellschaft für angewandte Forschung e.V. Verapido Medical GmbH, Villingen-Schwenningen, Germany)

Coffee Break & Posters

SESSION 9:
LATEBREAKER SESSION

Moderator: To be confirmed

Latebreaker abstracts for oral and poster presentation at SVS 2022 are called for. Please see the Participation page for details.

Lunch Break & Posters Breakdown

SESSION 10:
PANEL DISCUSSION

‘Transdermal Vaccination: Forward Directions’

Moderator: Shreemanta K. Parida
(Karolinska Institute, Stockholm, Sweden)

‘Circles’ – A new map of the viruses that predicts epidemics’
Nick Kulik
(Virology Department, ESC ‘Institute of Biology and Medicine’, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine)

‘The best ways IT can help us better understand viruses’
Nick Kulik
(Virology Department, ESC ‘Institute of Biology and Medicine’, Taras Shevchenko National University of Kyiv, Kyiv, Ukraine)

This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.